Biotechnology News and Research

RSS

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

New novel explores conflicts between need for scientific truth and drive for commercial success

Research scientist Jennifer Rohn's newly released novel, The Honest Look, set in a start-up biotechnology company, explores conflicts between the need for scientific truth and the drive for commercial success.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010

New findings could drive medical advances in genetic disorders that cause infertility

A hormone responsible for the onset of puberty can end up stuck in the wrong part of the body if the nerve pathways responsible for its transport to the brain fail to develop properly, according to research funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

30 Nov 2010

biOasis commences research agreement with NRC

biOasis Technologies Inc. announced today that it has commenced a sponsored research agreement with the National Research Council of Canada. Under the terms of the agreement, the NRC will evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Apricus Biosciences, Inc., announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

SuperSonic Imagine receives €19 million from historical investors

SuperSonic Imagine's historical investors, Edmond de Rothschild Investment Partners, Auriga Partners, Crédit Agricole Private Equity, NBGI Ventures, BioAm (managed by CDC Entreprises), Wellington Partners and IXO Private Equity, reiterated their strong support through a combined investment of €19 million in this round.

29 Nov 2010

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).

29 Nov 2010

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of its next-generation Qubit® 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment. The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.

29 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

QLT Inc. today announced that its wholly-owned U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"), and Quantel Medical and its distributor, Quantel USA, Inc., have entered into a co-promotion agreement for the sale of Activis PDT Lasers used to activate Visudyne® during photodynamic therapy of primarily classic lesions in wet age-related macular degeneration (AMD). The lasers are manufactured by Quantel Medical and sold by Quantel USA, Inc. and will be promoted by both Quantel USA, Inc. and QOI's sales force to the retina community in the United States.

29 Nov 2010

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.

29 Nov 2010

BioTime, CIRM enter agreement for GMP-grade hES cell lines

BioTime, Inc. today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation.

29 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

Biotechnology News and Research

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

New novel explores conflicts between need for scientific truth and drive for commercial success

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

New findings could drive medical advances in genetic disorders that cause infertility

biOasis commences research agreement with NRC

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

SuperSonic Imagine receives €19 million from historical investors

Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer

Spectrum's FUSILEV sNDA accepted by FDA for review

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

BioTime, CIRM enter agreement for GMP-grade hES cell lines

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News